On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > ACADEMIA
ACADEMIA
- Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
- Japan Succeeds in Isolating Novel Coronavirus Variant
January 7, 2021
- NCGM, Fujita Univ. to Join NIH’s Immunoglobulin Trial for COVID-19
December 24, 2020
- Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
- 4 Scientific Societies Call for COVID-19 Vaccine Recipient Registry
November 30, 2020
- Chugai’s Multigene Panel Test Difficult to Use as CDx, Reimbursement Rules Should Be Revised: KOL
November 25, 2020
- 5-Year Cancer Survival Rate at 68.6%, Largely Unchanged: NCC
November 24, 2020
- National Cancer Center Exploring Effectiveness of Frontline Use of Multigene Panel Testing for Solid Tumors
November 18, 2020
- University of the Ryukyus to Test Gout Drug Colchicine for COVID-19
November 6, 2020
- 1st Cancer Patient Undergoes Transplant of iPSC-Derived NKT Cells: Chiba Univ., RIKEN
October 23, 2020
- NCC Verifies Utility of Genomic Analysis by Liquid Biopsy
October 7, 2020
- Japanese Nephrology Society Publishes Recommendation on Use of HIF-PH Inhibitors
October 2, 2020
- Personalized Approach Needed for HFpEF Treatment with Entresto: Professor
August 28, 2020
- Fabricated Data Found in 5 Papers by Ex-NCVC/Osaka Univ. Doctor; 1 Used to Design JANP Study
August 21, 2020
- Generic APIs at Crossroads - 4: Professor Calls for Monitoring Drugs Liable to Be in Short Supply, Drawing Up Lists of Substitutes
August 17, 2020
- Generic APIs at Crossroads - 3: Gx Society Sets Up Committee for Discussions with Healthcare Providers and API Manufacturers
August 14, 2020
- Infectious Diseases Society Proposes Testing for Both COVID-19, Flu as It Girds for Simultaneous Outbreaks
August 7, 2020
- NCC, BrightPath Identify Peptide Vaccine Candidates for COVID-19
July 31, 2020
- Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
- Univ. of Tokyo, Biogen Expand Neurological Research Program for 2 Years
July 9, 2020
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…